Veru Inc (NASDAQ:VERU) Expected to Announce Quarterly Sales of $10.68 Million

Equities research analysts predict that Veru Inc (NASDAQ:VERU) will post sales of $10.68 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Veru’s earnings, with the highest sales estimate coming in at $12.00 million and the lowest estimate coming in at $10.00 million. Veru posted sales of $9.73 million during the same quarter last year, which would indicate a positive year over year growth rate of 9.8%. The firm is expected to report its next quarterly earnings report on Thursday, August 13th.

On average, analysts expect that Veru will report full year sales of $42.61 million for the current fiscal year, with estimates ranging from $40.81 million to $46.00 million. For the next year, analysts forecast that the firm will post sales of $50.12 million, with estimates ranging from $42.85 million to $54.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Veru.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The firm had revenue of $9.94 million for the quarter, compared to the consensus estimate of $11.06 million. Veru had a negative net margin of 25.53% and a negative return on equity of 31.14%.

VERU has been the topic of several recent research reports. ValuEngine downgraded shares of Veru from a “buy” rating to a “hold” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Veru in a research report on Wednesday, May 6th. Zacks Investment Research raised shares of Veru from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Saturday, May 16th. BidaskClub cut shares of Veru from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 4th. Finally, Oppenheimer raised their target price on shares of Veru to $9.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $7.40.

NASDAQ:VERU traded down $0.15 during mid-day trading on Friday, hitting $3.44. The stock had a trading volume of 420,800 shares, compared to its average volume of 391,541. The stock has a market capitalization of $237.28 million, a price-to-earnings ratio of -22.93 and a beta of 0.49. The company has a 50 day simple moving average of $3.54 and a 200-day simple moving average of $3.36. Veru has a 52 week low of $1.67 and a 52 week high of $4.74. The company has a current ratio of 1.04, a quick ratio of 0.68 and a debt-to-equity ratio of 0.07.

Several institutional investors and hedge funds have recently made changes to their positions in VERU. Renaissance Technologies LLC grew its stake in shares of Veru by 128.4% in the 4th quarter. Renaissance Technologies LLC now owns 902,911 shares of the company’s stock worth $3,025,000 after purchasing an additional 507,598 shares during the last quarter. Morgan Stanley grew its stake in shares of Veru by 12,842.8% in the 1st quarter. Morgan Stanley now owns 323,569 shares of the company’s stock worth $1,058,000 after purchasing an additional 321,069 shares during the last quarter. EAM Investors LLC acquired a new position in shares of Veru in the 4th quarter worth approximately $1,009,000. Two Sigma Investments LP acquired a new position in shares of Veru in the 1st quarter worth approximately $383,000. Finally, Credit Suisse AG acquired a new position in shares of Veru in the 4th quarter worth approximately $375,000. 16.49% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: What are Institutional Investors?

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.